In Q2 2023, Tang Capital Management held 65 positions worth $486.4M. They initiated 14 new positions and exited 10. Their largest holding was ANAB ($39.7M). Portfolio value grew +4.2% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q2 2023?
Tang Capital Management held 65 biotech stocks in their 13F portfolio in Q2 2023. Their top positions include ANAB, TARS, MIRM, IMCR, KALV. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q2 2023?
Tang Capital Management's tracked biotech portfolio was worth $486.4M across 65 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q2 2023?
Tang Capital Management initiated 14 new positions in Q2 2023, including IFRX, VSTM, ADMA, NVCR, PHAT and 9 more. They also increased 10 existing positions.
What did Tang Capital Management sell in Q2 2023?
Tang Capital Management fully exited 10 positions in Q2 2023, including VNDA, SCYX, RXDX, ITOS, TIL and 5 more. They also trimmed 12 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Management portfolio →